MHLW (Japan) approves Tavalisse to
treat chronic idiopathic thrombocytopenic purpura.- Kissei
Kissei Pharmaceutical Co., Ltd. announced that the Ministry of Health, Labour and Welfare (MHLW) has granted manufacturing and marketing approval to Kissei for the oral spleen tyrosine kinase (SYK) inhibitor, Tavalisse Tab. 100mg and 150mg (generic name: fostamatinib disodium hexahydrate, development code: R788), for chronic idiopathic thrombocytopenic purpura (chronic ITP).